Search results for "Non small cell"

showing 10 items of 68 documents

Upfront radiation versus EGFR-TKI : which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?

2017

In The Journal of Clinical Oncology , William J. Magnuson (1) and colleagues have recently reported the results of a multicenter retrospective analysis comparing the impact of three different treatment strategies on survival outcomes of 351 patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and brain metastases (BM). Treatment options included stereotactic radiosurgery (SRS) followed by EGFR-TKI (n=100), whole-brain radiotherapy (WBRT) followed by EGFR-TKI (n=120), or EGFR-TKI followed by SRS or WBRT at the time of intracranial progression (n=131). Results showed a significantly longer median overall survival (OS) in patients who received upfron…

Oncologymedicine.medical_specialtyRadiology Nuclear Medicine and ImagingCancer Researchmedicine.medical_treatmentOncology; Radiology Nuclear Medicine and Imaging; Cancer ResearchRadiosurgeryOncology; Radiology; Nuclear Medicine and Imaging; Cancer ResearchEgfr tkiInternal medicineNuclear Medicine and ImagingmedicineIn patientEpidermal growth factor receptorClinical Oncologybiologybusiness.industrymedicine.diseaserespiratory tract diseasesRadiation therapyOncologybiology.proteinNon small cellHuman medicinebusinessRadiologyBrain metastasisTRANSLATIONAL CANCER RESEARCH
researchProduct

Mortality in early-stage, surgically resected non-small cell lung cancer less than 3cm of size: Competing risk analysis

2015

Abstract Background and objective Survival studies of non-small cell lung cancer (NSCLC) are usually based on the Kaplan–Meier method. However, other factors not covered by this method may modify the observation of the event of interest. There are models of cumulative incidence (CI), that take into account these competing risks, enabling more accurate survival estimates and evaluation of the risk of death from other causes. We aimed to evaluate these models in resected early-stage NSCLC patients. Patients and method This study included 263 patients with resected NSCLC whose diameter was ≤3 cm without node involvement (N0). Demographic, clinical, morphopathological and surgical variables, TN…

Oncologymedicine.medical_specialtyUnivariate analysisMultivariate analysisbusiness.industryCancerCompeting risksmedicine.diseaseSurgeryInternal medicinemedicineCumulative incidenceNon small cellStage (cooking)businessLung cancerMedicina Clínica (English Edition)
researchProduct

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

Upregulated Mirna 21 in Kras Mutated Patients is Related to Prognosis in Resectable Non-Small Cell Lung Cancer

2015

Oncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseasemedicine.disease_causeOncologyInternal medicineMutation (genetic algorithm)microRNAmedicineNon small cellKRASbusinessLung cancerAnnals of Oncology
researchProduct

The role of second and third line tyrosine kinase inhibitor monotherapy in EGFR wild-type (and unknown mutational status) advanced non-small-cell lun…

2015

Oncologymedicine.medical_specialtybusiness.industrymedicine.drug_classWild typeHematologymedicine.diseaseTyrosine-kinase inhibitorOncologyThird lineInternal medicinemedicineRetrospective analysisMutational statusNon small cellbusinessLung cancerAnnals of Oncology
researchProduct

Neuroendocrine Neoplasms (NENs)

2021

Neuroendocrine neoplasms (NENs) represent a rare and heterogeneous group of malignancies which can develop in many different sites of our body. They originate from the cells of the diffuse neuroendocrine system. Gastroenteropancreatic NENs were classified in four categories, including NETs G1 (WD with 20% Ki-67), and NECs (PD with >20% Ki-67) in accordance with the 2019 WHO classification (IARC WHO Classification of the digestive system tumors, on 11th July 2019). Lung NENs, in accordance with the latest WHO classification, 2015 edition, are distinguished in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), atypical carcinoid (AC), and typical carcinoid (TC).

Pathologymedicine.medical_specialtyHeterogeneous groupLungmedicine.anatomical_structurebusiness.industryMedicineTypical carcinoidNon small cellLarge-cell neuroendocrine carcinomaWho classificationbusinessAtypical carcinoid
researchProduct

Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?

2006

Pathologymedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentPlatinum Compounds.Medical OncologyCarboplatinchemistry.chemical_compoundCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansLung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryRespiratory diseasePlatinum compoundsHematologyPrognosismedicine.diseaseCarboplatinOncologychemistryCancer researchNon small cellCisplatinbusinessmedicine.drug
researchProduct

Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study

2022

Abstract Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. Methods The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. Results For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input …

Predictive molecular pathologyLung NeoplasmsTotal costCostCost; NGS; NSCLC; Predictive molecular pathology; Single-gene test; Algorithms; High-Throughput Nucleotide Sequencing; Humans; Italy; Multicenter Studies as Topic; Carcinoma Non-Small-Cell Lung; Lung NeoplasmsNSCLCRobustness (computer science)Carcinoma Non-Small-Cell LungCost evaluationMedicineHumansMulticenter Studies as TopicNon-Small-Cell LungMolecular pathologybusiness.industryCarcinomaHigh-Throughput Nucleotide SequencingHematologyReliability engineeringWorkflowOncologyEconomic sustainabilityItalyNGSSingle-gene testNon small cellbusinessAlgorithms
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct

Bcl-2, Bcl-xl, and pp32/PHAPI in resected non-small-cell lung cancer patients

2009

Einleitung: Fur viele Tumorarten ist der Einfluss des Apoptosesignalweges auf die Prognose der Tumorerkrankung beschrieben worden. So konnte fur die antiapoptotischen Proteine wie Bcl-2 und Bcl-xL gezeigt werden, dass sie den mitochondrialen Selbstzerstorungsmechanismus der Zellen herunterregulieren konnen. Fur nicht-kleinzellige Lungenkarzinomen (NSCLC) hingegen existieren widerspruchliche Angaben in der wissenschaftlichen Literatur in Bezug auf die prognostische Wertigkeit apoptotischer und insbesondere antiapoptotischer Faktoren. Ein weiterer wichtiger Faktor im genannten Mechanismus, welches NSCLC fur apoptotische Stimuli sensibilisieren soll, ist das Protein pp32/PHAPI. Fur bereits che…

Pulmonary and Respiratory MedicineBcl 2 bcl xlbusiness.industryCancer researchMedicineNon small cellbusinessLung cancermedicine.diseaseMolecular biologyPneumologie
researchProduct